Session Details

F069 Chronic Urticaria: What's New

Mon, Mar 22, 9:00 AM - 11:00 AM
2 CME Available Forum

DESCRIPTION

The purpose of this session is to highlight the recent major advances in this field as CSU and CIndU cases continue to persist despite being treated with antihistamines, and Omalizumab. New targeted treatments Dupilumab and Remibrutinib have been approved for use in CSU the last year . Furthermore dermatologists will be presented with diagnostic and treatment algorithms based on evidence-based guidelines, and patient specific factors. In addition the dermatologists will be presented with and new drugs in the pipeline that target CSU and CIndU.

LEARNING OBJECTIVES

1.

Recognize Spontaneous CU (CSU) and Inducible CU (CIndU) through identification of the clinical symptoms and associated biomarker testing

2.

Describe evidence-based strategies for treatment selection considering clinical guidelines and patient-specific factors

3.

Review and describe the mechanisms of CSU and emerging biologic therapies and small molecules in the treatment of CSU and CIndU

SCHEDULE

9:00 AM

Intro

Gil Yosipovitch, MD

9:05 AM

Pathophyisology of Chronic Urticaria

Brian S. Kim, MD, FAAD

9:25 AM

chronic inducible urticaria ;Whats new

9:45 AM

CSU Guidelines of Chronic Urticaria; Whats New and What are the remaining challenges

Martin Metz, MD

10:10 AM

New And Emerging Treatments for Chronic Urticaria

Jason Ezra Hawkes, MD, MS, FAAD

DIRECTOR

Gil Yosipovitch, MD

Gil Yosipovitch, MD

Miller School of Medicine, Florida

SPEAKERS

Ana M. Gimenez-Arnau, MD, IFAAD

Ana M. Gimenez-Arnau, MD, IFAAD

Brian S. Kim, MD, FAAD

Brian S. Kim, MD, FAAD

Martin Metz, MD

Martin Metz, MD

Charité - University Medical Center Berlin, Germany

DISCLOSURES

Ana M. Gimenez-Arnau, MD, IFAAD

Almirall – Advisory Board(Fees); Amgen – Advisory Board(Fees); AstraZeneca – Investigator(Grants/Research Funding); Avene – Speaker(Fees); Blueprint Medicines – Advisory Board(Fees); Celldex – Investigator(Grants/Research Funding); celtrium – Advisory Board(Honoraria); Escient – Investigator(Grants/Research Funding); Evommune – Advisory Board(Honoraria); Genentech – Investigator(Grants/Research Funding); Grupo Menarini Centroamerica – Speaker(Fees); GSK – Advisory Board(Fees); Harmonic Bio – Advisory Board(No Compensation Received); Incyte Corporation – Advisory Board(No Compensation Received); Instituto de Salud Carlos III – Investigator(Grants/Research Funding); Jasper Therapeutics – Advisory Board(Fees); Leo Pharma – Investigator(Grants/Research Funding); Mitsubishi Tanabe Pharma Development America – Advisory Board(Fees); Noucor, – Advisory Board(Fees); Novartis Pharmaceuticals Corp. – Advisory Board(Fees), Investigator(Grants/Research Funding); Pfizer – Advisory Board(No Compensation Received); RAPT Therapeutics – Advisory Board(Honoraria); Sanofi–Regeneron – Advisory Board(Fees), Investigator(Grants/Research Funding); Septerna – Advisory Board(Fees); Servier – Advisory Board(Fees);

Brian S. Kim, MD, FAAD

AbbVie – Consultant(Fees); Almirall – Advisory Board(Honoraria); Alys Pharmaceuticals – Stockholder Private Company(Stock); AstraZeneca – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Advisory Board(Honoraria); Evommune, Inc. – Consultant (1099 relationship)(Fees); Galderma – Consultant (1099 relationship)(Fees); Guidepoint Global, LLC – Consultant(Fees); Leo Pharma Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Locus Biosciences – Stockholder(Stock); Novartis – Advisory Board(Honoraria); Pfizer Inc. – Consultant(Honoraria); Recens Medical – Consultant(Fees); Regeneron – Consultant (1099 relationship)(Honoraria); Sanofi – Consultant(Fees); Septerna – Consultant (1099 relationship)(Fees);

Martin Metz, MD

AbbVie – Speaker(Honoraria); Allakos – Investigator(No Compensation Received); Allegria Therapeutics – Advisory Board(Honoraria); Almirall – Speaker(Honoraria), Speaker/Faculty Education(Honoraria); Amgen – Advisory Board(Honoraria); Arcutis Biotherapeutics – Advisory Board(Honoraria); argenx – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); AstraZeneca – Advisory Board(Honoraria); Astria Therapeutics – Advisory Board(Honoraria); Attovia Therapeutics – Consultant (1099 relationship)(Honoraria); Bayer – Consultant (1099 relationship)(Honoraria); Berlin Chemie – Speaker(Honoraria); Blueprint Medicines – Advisory Board(Honoraria); candid – Consultant (1099 relationship)(Honoraria); Celldex – Advisory Board(Honoraria); Celltrion – Speaker(Honoraria); Deep Apple Therapeutics – Advisory Board(Honoraria); Eli Lilly – Advisory Board(Honoraria); Enanta Pharmaceuticals – Consultant (1099 relationship)(Honoraria); Escient Pharmaceuticals, Inc – Advisory Board(Honoraria); Evommune, Inc. – Advisory Board(Honoraria); Excellergy – Consultant (1099 relationship)(Honoraria); FatiAbGen – Consultant (1099 relationship)(Honoraria); Galderma – Advisory Board(Honoraria), Speaker(Honoraria); Generate Biomedicines – Consultant (1099 relationship)(Honoraria); GlaxoSmithKline Immunology – Advisory Board(Honoraria); Granular Therapeutics – Advisory Board(Honoraria); Incyte Corporation – Advisory Board(Honoraria); InflaRx – Consultant (1099 relationship)(Honoraria); Japan Tobacco Inc. – Consultant (1099 relationship)(Honoraria); Jasper Therapeutics – Advisory Board(Honoraria); Johnson & Johnson Pharmaceutical Research & Development – Advisory Board(Honoraria); Lycia Therapeutics – Consultant (1099 relationship)(Honoraria); Novartis – Advisory Board(Honoraria), Speaker(Honoraria); Ono – Consultant (1099 relationship)(Honoraria); Pfizer Inc. – Speaker(Honoraria); RAPT Therapeutics – Advisory Board(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria), Speaker(Honoraria); Santa Ana Bio – Advisory Board(Honoraria); Septerna – Advisory Board(Honoraria); Tupos – Consultant (1099 relationship)(Honoraria);

Gil Yosipovitch, MD

AbbVie – Advisory Board(Honoraria); Arcutis, Inc. – Advisory Board(Honoraria); Cara Therapeutics – Advisory Board(Honoraria); CeraVe – Advisory Board(Honoraria); Eli Lilly – Investigator(Fees), Investigator(Grants/Research Funding); Eli Lilly and Company – Advisory Board(Honoraria); escient – Investigator(Fees), Investigator(Grants/Research Funding); Galderma – Advisory Board(Honoraria); Galderma Laboratories, L.P. – Consultant(Honoraria), Investigator(Fees), Investigator(Grants/Research Funding); GSK – Advisory Board(Honoraria); Kamari Pharma – Consultant(Fees); Kiniksa Pharmaceuticals, Ltd. – Investigator(Grants/Research Funding); Maruho Co., Ltd – Speaker/Faculty Education(Fees); Novartis – Consultant(Honoraria), Investigator(Fees), Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Pierre Fabre – Consultant(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria), Investigator(Fees), Investigator(Grants/Research Funding); Vifor Pharma – Consultant(Fees);